| abstract |
The invention provides an isolated, dual-specific antibody, or an antigen-binding portion thereof, which is specific for human IL-l α and human IL-I β. The dual specific antibodies of the invention also neutralize both human IL-I α and human IC-I β. The invention also provides domain antibodies (dAbs) specific for human IL-l α and human IL-l β. |